{
    "2019-09-03": [
        [
            {
                "time": "2018-03-15",
                "original_text": "UK cost watchdog recommends Novartis' blindness therapy Luxturna",
                "features": {
                    "keywords": [
                        "UK",
                        "cost",
                        "watchdog",
                        "recommends",
                        "Novartis'",
                        "blindness",
                        "therapy",
                        "Luxturna"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Global Blood Focuses on Lead Candidate Amid Competition",
                "features": {
                    "keywords": [
                        "Global",
                        "Blood",
                        "Focuses",
                        "Lead",
                        "Candidate",
                        "Competition"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "5 Cancer-Fighting Stocks to Add to Your Portfolio",
                "features": {
                    "keywords": [
                        "Cancer-Fighting",
                        "Stocks",
                        "Portfolio"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "Vertex snaps up Cambridge diabetes startup Semma for $950M",
                "features": {
                    "keywords": [
                        "Vertex",
                        "snaps",
                        "Cambridge",
                        "diabetes",
                        "startup",
                        "Semma",
                        "$950M"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "UPDATE 1-Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals",
                "features": {
                    "keywords": [
                        "UPDATE",
                        "Novartis",
                        "Lonza",
                        "biosimilars",
                        "MS",
                        "arthritis",
                        "drug",
                        "deals"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-08-05",
                "original_text": "Novartis's Sandoz licenses proposed multiple sclerosis biosimilar",
                "features": {
                    "keywords": [
                        "Novartis's",
                        "Sandoz",
                        "licenses",
                        "proposed",
                        "multiple",
                        "sclerosis",
                        "biosimilar"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}